COSMOS Pharmaceutical Corporation
CSMYFOTCHealthcare● Active
$41.20
+$4.14(+11.17%)
Market Cap$3.3B
P/E Ratio—
52W High$48.271
52W Low$37.06
COSMOS Pharmaceutical Corporation (CSMYF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CSMYF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 13, 2026EPS Actual
$0.66
Est. $0.65 · +1.6%
Revenue
$1.75B
Est. $1.72B · +1.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 13, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
CSMYF reports quarterly as a OTC-listed Medical - Pharmaceuticals company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.03
Rev. $1.54B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.03
Rev. Est.$1.54B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 13, 2026 | $0.74 | — | — | — | $1.79B | — |
| ▲ Q2 FY2026 | Apr 13, 2026 | $0.65 | $0.66 | +1.6% | $1.75B | $1.72B | +1.7% |
| ▼ Q1 FY2026 | Jan 13, 2026 | $0.54 | $0.52 | -2.8% | $1.70B | $1.68B | +1.1% |
| ▼ Q4 FY2025 | Oct 14, 2025 | $0.76 | $0.70 | -8.0% | $1.85B | $1.87B | -0.8% |
| ▼ Q3 FY2025 | Jul 10, 2025 | $0.78 | $0.76 | -2.8% | $1.80B | $1.79B | +0.5% |
| ▲ Q2 FY2025 | Apr 14, 2025 | $0.51 | $0.66 | +30.8% | $1.64B | $1.66B | -1.5% |
| ▲ Q1 FY2025 | Jan 10, 2025 | $0.43 | $0.53 | +23.8% | $1.63B | $1.64B | -0.7% |
| ▲ Q4 FY2024 | Oct 11, 2024 | $0.61 | $0.70 | +15.8% | $1.79B | $1.79B | +0.1% |
Q3 FY2026
Jul 13, 2026
EPS Actual
—
EPS Est.
$0.74
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 13, 2026Beat
EPS Actual
$0.66
EPS Est.
$0.65
EPS Surpr.
+1.6%
Revenue
$1.75B
Q1 FY2026
Jan 13, 2026Miss
EPS Actual
$0.52
EPS Est.
$0.54
EPS Surpr.
-2.8%
Revenue
$1.70B
Q4 FY2025
Oct 14, 2025Miss
EPS Actual
$0.70
EPS Est.
$0.76
EPS Surpr.
-8.0%
Revenue
$1.85B
Q3 FY2025
Jul 10, 2025Miss
EPS Actual
$0.76
EPS Est.
$0.78
EPS Surpr.
-2.8%
Revenue
$1.80B
Q2 FY2025
Apr 14, 2025Beat
EPS Actual
$0.66
EPS Est.
$0.51
EPS Surpr.
+30.8%
Revenue
$1.64B
Q1 FY2025
Jan 10, 2025Beat
EPS Actual
$0.53
EPS Est.
$0.43
EPS Surpr.
+23.8%
Revenue
$1.63B
Q4 FY2024
Oct 11, 2024Beat
EPS Actual
$0.70
EPS Est.
$0.61
EPS Surpr.
+15.8%
Revenue
$1.79B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2026 | $115.96 | $117.34 | $119.16 | 1 |
| Q1 FY2026 | $99.79 | $100.98 | $102.54 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $301B | $304B | $308B | 2 |
| Q1 FY2027 | $289B | $291B | $295B | 2 |
| Q4 FY2026 | $281B | $284B | $287B | 1 |
| Q3 FY2026 | $293B | $295B | $299B | 3 |
| Q2 FY2026 | $279B | $286B | $291B | 7 |
| Q1 FY2026 | $263B | $269B | $275B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 13, 2026 | +1.6% | $48.27 | $48.27 | +0.00% |
| ▼ Q1 FY2026 | Jan 13, 2026 | -2.8% | $48.27 | $48.27 | +0.00% |
| ▼ Q4 FY2025 | Oct 14, 2025 | -8.0% | $46.06 | $46.06 | +0.00% |
| ▼ Q3 FY2025 | Jul 10, 2025 | -2.8% | $46.06 | $46.06 | +0.00% |
| ▲ Q2 FY2025 | Apr 14, 2025 | +30.8% | $46.06 | $46.06 | +0.00% |
| ▲ Q1 FY2025 | Jan 10, 2025 | +23.8% | $49.22 | $46.06 | -6.42% |
| ▲ Q4 FY2024 | Oct 11, 2024 | +15.8% | $39.30 | $39.30 | +0.00% |
| ▼ Q3 FY2024 | Jul 12, 2024 | -7.2% | $49.16 | $49.16 | +0.00% |
Q2 FY2026+0.00%
Report Date
Apr 13, 2026
EPS Beat/Miss
+1.6%
Price Before
$48.27
Price After
$48.27
Q1 FY2026+0.00%
Report Date
Jan 13, 2026
EPS Beat/Miss
-2.8%
Price Before
$48.27
Price After
$48.27
Q4 FY2025+0.00%
Report Date
Oct 14, 2025
EPS Beat/Miss
-8.0%
Price Before
$46.06
Price After
$46.06
Q3 FY2025+0.00%
Report Date
Jul 10, 2025
EPS Beat/Miss
-2.8%
Price Before
$46.06
Price After
$46.06
Q2 FY2025+0.00%
Report Date
Apr 14, 2025
EPS Beat/Miss
+30.8%
Price Before
$46.06
Price After
$46.06
Q1 FY2025-6.42%
Report Date
Jan 10, 2025
EPS Beat/Miss
+23.8%
Price Before
$49.22
Price After
$46.06
Q4 FY2024+0.00%
Report Date
Oct 11, 2024
EPS Beat/Miss
+15.8%
Price Before
$39.30
Price After
$39.30
Q3 FY2024+0.00%
Report Date
Jul 12, 2024
EPS Beat/Miss
-7.2%
Price Before
$49.16
Price After
$49.16
Avg Beat Reaction-1.60%
Avg Miss Reaction+0.00%
Beat Rate4 / 8 quarters
Largest Move-6.42% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CSMYF ends December
COSMOS Pharmaceutical Corporation (CSMYF) most recently reported earnings on April 13, 2026 for Q2 FY2026, posting EPS of $0.66 — beating the analyst consensus of $0.65 by +1.6%. The next CSMYF earnings date is expected around September 1, 2026.
Each quarter, investors track CSMYF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CSMYF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CSMYF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CSMYF earnings · 5 questionsCOSMOS Pharmaceutical Corporation's next earnings report is expected around September 1, 2026. CSMYF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CSMYF historically reports after market close (AMC).
CSMYF earnings datewhen is CSMYF earningsCSMYF next earnings datewhen does CSMYF report earningsCSMYF earnings calendar
▸ Source: FMP · COSMOS Pharmaceutical Corporation SEC filings · US GAAP · COSMOS Pharmaceutical Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026